Background {#Sec1}
==========

Hepatocellular carcinoma (HCC) involving a major branch of the portal or hepatic vein occurs in a locally advanced stage. Although molecular targeted therapy is the standard treatment for locally advanced HCC (LAHCC), according to the European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer practical guidelines \[[@CR1]\], LAHCC treated with molecular targeted therapy alone has shown dismal prognosis \[[@CR2]--[@CR4]\]. Therefore, radiotherapy, transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy, and/or percutaneous radiofrequency ablation (RFA) were performed in LAHCC patients as an additional treatment. Recently, the report by Yoon et al. showed that TACE combined with X-ray RT improved the prognosis compared with molecular targeted therapy alone in a randomized controlled trial \[[@CR5]\].

Carbon ion radiotherapy (C-ion RT) provides both, physical and biological advantages over X-ray RT, and several researchers have shown favorable clinical outcomes in HCC patients when they were treated with C-ion RT \[[@CR6]--[@CR9]\]. In the physical aspect, previous studies have demonstrated a dose distribution advantage, showing that a reduced dose was delivered to the liver using C-ion RT compared with those of stereotactic body RT (SBRT) and intensity-modulated RT (IMRT) \[[@CR10], [@CR11]\]. This was achieved owing to the physical nature of the C-ion RT procedure with distal tail-off due to the Bragg Peak and a sharp lateral penumbra \[[@CR12]\]. Additionally, in the biological aspect, the C-ion beams have higher linear energy transfer than X-rays, and thus have superior cell-killing effect in radioresistant tumor cells such as hypoxic and cancer stem cells \[[@CR13], [@CR14]\]. Although there is lack of data on the clinical outcomes in patients with LAHCC treated with C-ion RT, these advantages of C-ion RT may contribute to the improved prognosis of multidisciplinary treatment of LAHCC. Hence, in the current study, we analyzed the treatment outcomes of C-ion RT in patients with LAHCC.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

We reviewed the medical records of 124 patients treated with C-ion RT for HCC at the Gunma University Heavy Ion Medical Center (GHMC) between July 2011 and August 2018. Eleven consecutive patients met the following criteria: 1) HCC involving a major branch of the portal or hepatic vein confirmed by histology or typical hallmarks of HCC using imaging techniques of four-phase multidetector-row computed tomography (CT) or dynamic contrast-enhanced magnetic resonance imaging (MRI) (hypervascular in the arterial phase with washout in the portal venous or delayed phase); 2) no intrahepatic metastasis or distant metastasis; 3) no findings suggesting direct infiltration of the gastrointestinal (GI) tract; 4) performance status (PS) ≤ 2 by Eastern Cooperative Oncology Group classification; and 5) Child-Pugh classification A or B. The definitions of the portal or hepatic vein and the Barcelona Clinic Liver Cancer (BCLC) classifications \[[@CR15], [@CR16]\] were determined using CT, MRI, ultrasonography, and other modalities. The albumin-bilirubin grade, by combining serum albumin and bilirubin, was calculated to evaluate liver function in all patients \[[@CR17]\]. In the current study, recurrent HCC treated with TACE and/or hepatic arterial infusion chemotherapy and/or RFA was included. The treatment protocol was reviewed and approved by the Gunma University Institutional Review Board, and all patients signed an informed consent form before the initiation of therapy.

Carbon ion radiotherapy {#Sec4}
-----------------------

A heavy-ion accelerator at the GHMC was used to generate C-ion beams, and beam energies of 290 MeV/u, 380 MeV/u, and 400 MeV/u were selected according to the depth of the tumor. Doses of C-ion RT were expressed in Gy (relative biological effectiveness \[RBE\]), defined as the physical dose multiplied by the RBE of the C-ions \[[@CR18], [@CR19]\].

Treatment-planning CT and contrast-enhanced CT images were merged to precisely delineate the gross tumor volume (GTV). The clinical target volume (CTV) was defined as GTV plus 5 mm in all directions and modified to include microscopic disease progression and to exclude the GI tract and portal vein. A fiducial marker was inserted near the tumor before CT acquisition. Marker motion was measured from four-dimensional CT images, and a margin was calculated from marker motion by the motion management procedure \[[@CR20]\]. The planning target volume (PTV) was generated by adding the margin to the CTV.

Prescribed doses were 52.8 Gy (RBE) or 60.0 Gy (RBE), delivered in four fractions for standard cases and the 60.0 Gy (RBE) delivered in 12 fractions for close-to-GI-tract cases. Close-to-GI-tract was defined as a distance of \< 1 cm between the tumor and the GI tract. The planning aim was to cover the PTV with at least 95% of the prescribed dose. The dose constraints were as follows: D~1cc~ \< 40 Gy (RBE) administered to the GI tract in the standard cases, D~1cc~ \< 45 Gy (RBE) administered to the GI tract in the close-to-GI-tract cases, V~20~ \< 35% administered to the liver, D~max~ \< 52.8 Gy (RBE) administered outside the PTV at the porta hepatis (including the first branch of the portal vein and hepatic duct), D~max~ \< 45 Gy (RBE) administered to skin in the standard cases, and D~max~ \< 50 Gy (RBE) administered to skin in close-to-GI-tract cases \[[@CR8]\]. Beam fields between 2 and 6 (median 2) were selected to satisfy the dose constraints for each patient. Figure [1](#Fig1){ref-type="fig"} shows a representative case of the dose distribution and diagnostic imaging in LAHCC before C-ion RT. Fig. 1HCC in an 83-year-old female patient treated with C-ion RT. **a** MRI (early phase) before treatment. **b** MRI (late phase) before treatment. **c** CT (early phase) before treatment. **d** Dose distribution on axial CT images. Highlighted are: 95% (red), 90% (yellow), 80% (green), 70% (blue), 60% (pink), 50% (purple), 30% (light purple), and 10% (light blue) isodose curves (100% = 60 Gy \[RBE\]). The area within the red outline is GTV. CT, computed tomography; GTV, gross tumor volume; RBE, relative biological effectiveness

For patient positioning, bone structural matching (BM) was basically performed on the orthogonal X-ray images \[[@CR21]\]. The following positioning strategy was used according to the measured marker position from the BM position: BM was used if the absolute marker movement was less than 3 mm, with marker structural matching if the absolute movement was between 3 and 10 mm, and with a re-setup if the absolute movement was greater than 10 mm \[[@CR22], [@CR23]\]. After patient positioning, respiratory-gated irradiation was performed while monitoring the respiratory waveform detected from the respiratory sensor (Anzai Medical Co., Ltd., Tokyo, Japan).

Evaluation during follow-up {#Sec5}
---------------------------

Patients were followed up for 1 month after C-ion RT completion, and every 3 months thereafter. The follow-up examinations comprised a routine testing of blood cell counts and chemistry, and abdominal diagnostic imaging such as four-phase multidetector-row CT, dynamic contrast-enhanced MRI, or contrast-enhanced ultrasonography. Acute and late toxicities were graded according to the Common Terminology Criteria for Adverse Events, version 4.0, of the National Cancer Institute \[[@CR24]\]. Liver toxicity was also assessed according to the changes in the Child--Pugh class. Acute and late toxicities were evaluated as the highest grade of toxicity that occurred within 3 months and at 3 months' post initiation of C-ion RT, respectively. Local recurrence was defined as tumor regrowth, with contrast enhancement on CT, MRI, or ultrasonography in the irradiated field after C-ion RT.

Statistical analyses {#Sec6}
--------------------

All statistical analyses were performed using the Statistical Package for the Social Sciences, version 25.0 (IBM Inc., Armonk, NY, USA). Survival was measured from the date of C-ion RT initiation to the date of death or the most recent follow-up. Local control (LC) was defined as no evidence of local progression. Progression-free survival (PFS) was measured from the initiation of C-ion RT to the date of local progression, disease progression outside of the primary site, or death from any cause. Probabilities of overall survival (OS), LC, and PFS rates were calculated using the Kaplan-Meier method. Additionally, we assessed the percentage of the minimum dose that covered 98% of the target volume (D~98~) based on the dose--volume histogram (DVH) for the CTV.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

The clinical characteristics of 11 eligible patients are summarized in Table [1](#Tab1){ref-type="table"}. The median follow-up duration after C-ion RT was 36.4 (range: 4.3--86.2) months. The median patient age at the time of registration of C-ion RT was 76 (range: 57--86) years. The median tumor size was 53 (range: 27--119) mm. The numbers of treatment-naive and recurrent HCC patients were 1 and 10, respectively. The number of prior treatments of C-ion RT was one time in five patients, two times in three patients, eight times in one patient, and eleven times in one patient. In terms of prior treatment of C-ion RT for the target lesion, six patients had received TACE, two patients TACE and RFA, and two patients TACE and hepatic arterial infusion chemotherapy. Direct invasion in the major branch of the portal vein, the hepatic vein, or both portal and hepatic veins was observed in three (one with Vp4 and two with Vp3), five (one with Vv3 and four with Vv2), and three (all with Vp3 + Vv2) patients, respectively. Child-Pugh classes A and B were observed in 10 and 1 patients, respectively. The dose fractionation schedules were 52.8 Gy (RBE) in four fractions in two patients, 60 Gy (RBE) in four fractions in four patients, and 60 Gy (RBE) in 12 fractions in five patients. Table 1Patient characteristics (*N* = 11)CharacteristicsAge, years, median (range)76 (57--86)Tumor size, mm, median (range)53 (27--119)Sex, number Male:Female9:2Etiology Hepatitis C virus antibody positive4 Hepatitis B surface antigen positive3 NASH/NAFLD2 Unidentified2Prior treatment of C-ion RT TACE6 TACE and RFA2 TACE and hepatic artery infusion chemotherapy2 Treatment naïve1Site of direct invasion Major branch of the portal vein3 Major branch of the hepatic vein5 Both major branches of the portal vein and the hepatic vein3Child-Pugh class A:B10:1Barcelona Clinic Liver Classification Stage A:B:C2:0:9Albumin-Bilirubin Grade1:2a:2b:33:2:5:1Pretreatment AFP, IU/ml  \< 2006 200--4002  \> 4003Indocyanine green retention rate at 15 min  \< 15%5 15--30%4  \> 30%2 Median (range)15.9 (4.9--108.7)^†^*Abbreviations: AFP* alpha-fetoprotein, *C-ion RT* carbon ion radiotherapy, *NASH/NAFLD* non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, *RFA* percutaneous radiofrequency ablation, *TACE* transarterial chemoembolization

Clinical outcomes {#Sec9}
-----------------

We calculated probabilities of OS, LC, and PFS rates and determined the recurrence pattern. The OS, LC, and PFS curves of all the patients are shown in Fig. [2](#Fig2){ref-type="fig"}. The 3-year estimated OS, LC, and PFS rates were 64, 78, and 18%, respectively. At the time of analysis, recurrence after C-ion RT was observed in 10 patients; 1 patient had local recurrence, 1 had both local recurrence and intrahepatic recurrence outside of the target region, 1 had local recurrence after distant metastases to the lung, 6 had intrahepatic recurrence outside the target region, and 1 had intrahepatic recurrence outside the target region after distant metastases to the lung. The details of treatment after recurrence are summarized in Table [2](#Tab2){ref-type="table"}. A total of six patients died of HCC and one patient died of rectal cancer. Fig. 2Kaplan-Meier curves: overall survival (blue line), local recurrence (green line), and progression-free survival (red line) in all patients. Number at risk is shown below the Fig. OS, overall survival; LC, local control; PFS, progression-free survival; f/u, follow-upTable 2Treatment after recurrenceCase numberPFS duration (months)First site of recurrenceNumber of treatments after recurrenceSurgeryC-ion RTRFATACETAIMolecular targeted therapy11.7Intrahepatic recurrenceNoneNoneNone2NoneNone2^a^50.9Distant metastases (lung)None1NoneNoneNone1 (Lenvatinib)39.5Intrahepatic recurrenceNoneNoneNone1None1 (Sorafenib)424.7No recurrenceNoneNoneNoneNoneNoneNone59.3Intrahepatic recurrence1None13None2 (Sorafenib and Lenvatinib)6^b^12.2Distant metastases (lung)111None1None73.6Intrahepatic recurrenceNoneNone1NoneNone1 (Sorafenib)88.6Intrahepatic recurrenceNoneNone1NoneNone1 (Sorafenib)91.2Intrahepatic recurrenceNoneNoneNone1None1 (Lenvatinib)102.1Intrahepatic recurrenceNoneNoneNone1^c^NoneNone111.8Local recurrenceNoneNoneNoneNoneNoneNone^a^Patient in Case 2 had local recurrence after distant metastases to the lung and received C-ion RT for local recurrence as a re-irradiation^b^Patient in Case 6 had intrahepatic recurrence outside the target region after distant metastases to the lung, who received surgery for the lung metastases and C-ion RT for the intrahepatic recurrence^c^Patient in Case 10 received transarterial embolization^*¶*^*Abbreviations: C-ion RT* carbon ion radiotherapy, *PFS* progression-free survival, *RFA* percutaneous radiofrequency ablation, *TACE* transarterial chemoembolization, *TAI* transcatheter arterial infusion chemotherapy

In order to to identify the dosimetric parameters associated with local control after C-ion RT, we then performed a dose--volume analysis. The median CTV volume and CTV D~98~ on DVH analysis were 227 cm^3^ (range: 76--1090) and 57.1 Gy (RBE) (range: 47.5--59.9), respectively. Scatterplots of the CTV volume, CTV D~98~, and presence or absence of local recurrence are shown in Fig. [3](#Fig3){ref-type="fig"}. These plots revealed that patients with higher D~98~ tended to have locally controlled tumor regardless of CTV volume. One patient with high CTV D~98~ (red circle surrounded by a square) had local recurrence more than 5 years after the treatment with C-ion RT. Two patients with locally controlled tumors and low CTV D~98~ (blue circles surrounded by a triangle) were prescribed C-ion RT at a dose of 52.8 Gy (RBE). In the other two patients with a locally recurrent tumor and low CTV D~98~ (red circles in lower than 53 Gy \[RBE\] area), CTV D~98~ was lowered due to the priority given to the dose constraint over the GI tract. Patients with higher CTV D~98~ tended to have no local recurrence or long-term local control after C-ion RT. Fig. 3Scatterplots of the CTV volume, CTV D98, and presence or absence of local recurrence. Blue circles indicate tumor control cases and red circles indicate tumor recurrence cases. A red circle surrounded by a square indicates a case of local recurrence more than five years after C-ion RT, and blue circles surrounded by a triangle indicate cases of prescribed dose of 52.8 Gy (RBE) of C-ion RT. CTV, clinical target volume; RBE, relative biological effectiveness

Toxicities {#Sec10}
----------

All details of the observed acute and late toxicities are listed in Table [3](#Tab3){ref-type="table"}. No patient developed radiation-induced liver diseases, or grade 2 or higher toxicities in the acute and late phases. Two of 11 patients with Child-Pugh class A progressed to class B within 3 months after treatment with C-ion RT. After 3 months from the initiation of C-ion RT, 3 of 10 patients with Child-Pugh class A progressed to class B. No severe toxicities had developed in our study patients. Table 3Acute and late toxicities graded by CTCAE, version 4.0 (*N =* 11)Grade 0Grade 1Grade 2Grade 3Grade 4**Acute toxicities** Dermatitis29000 GI tract110000 Pneumonitis83000 Encephalopathy110000 Ascites92000**Late toxicities** Dermatitis38000 GI tract110000 Pneumonitis92000 Encephalopathy110000 Ascites92000 Bone fracture110010^†^*Abbreviations: CTCAE* Common Terminology Criteria for Adverse Events, *GI* gastrointestinal tract

Discussion {#Sec11}
==========

The current study demonstrated that C-ion RT showed favorable clinical outcomes in patients with LAHCC. In our study, the 3-year estimated OS, LC, and PFS rates were 64, 78, and 18%, respectively, with minimal toxicities. A previous study on C-ion RT outcomes in patients with HCC in a multi-institutional analysis, which did not include locally advanced cases, showed that 3-year LC rate was 81% \[[@CR9]\]. The result of LC shown in that study was similar to that in our study, although all patients analyzed had locally advanced disease cases. For various LAHCC treatments, the median OS in molecular targeted therapy ranged between 5.3 and 11.5 months \[[@CR3]--[@CR5], [@CR21]\], while that in hepatic arterial infusion chemotherapy with radiotherapy was 9.9 months \[[@CR25]\], and that in TACE-based multidisciplinary treatment ranged from 7.0 to 12.7 months \[[@CR5], [@CR26]\]; the 3-year OS rates in surgery based multidisciplinary treatment ranged from 13 to 68% \[[@CR15], [@CR27], [@CR28]\]. Additionally, Komatsu et al. reported on the comparison of clinical outcomes between LAHCC treated with particle therapy and liver resection in a matched-pair analysis \[[@CR29]\]. Clinical outcomes of these other anti-cancer treatments are summarized in Table [4](#Tab4){ref-type="table"}. They concluded that particle therapy was potentially preferable over liver resection in LAHCC. Although another anticancer therapy for LAHCC showed a wide range of outcomes in OS, the 3-year OS of 64% for C-ion RT-based multidisciplinary treatment shown in our study, appears to be comparable or favorable. Therefore, we propose that C-ion RT could be one of the therapy options for the multidisciplinary treatment of LAHCC. Table 4Comparison between the present study and the previous studies of LAHCCReferenceYearnTreatment MethodOSKudo M, et al. \[[@CR3]\]2018250LenvatinibMedian OS: 11.5 monthsBruix J, et al. \[[@CR4]\]2012108SorafenibMedian OS: 8.1 monthsYoon SM, et al. \[[@CR5]\])201845SorafenibMedian OS: 9.9 monthsKodama K, et al. \[[@CR21]\]201836SorafenibMedian OS: 5.3 monthsKodama K, et al. \[[@CR21]\]201836HAIC with RTMedian OS: 9.9 monthsYoon SM, et al. \[[@CR5]\]201845TACE with RTMedian OS: 12.7 monthsZhang X, et al.^a^ \[[@CR22]\]201721--604SorafenibMedian OS: 7.0--13.0 monthsKudo M, et al. \[[@CR15]\]20191101Surgery3y-OS: 40%Liu PH, et al. \[[@CR23]\]2014247Surgery3y-OS: 68%Shi J, et al. \[[@CR24]\]2010406Surgery3y-OS: 13%Komatsu S, et al. \[[@CR25]\]201719Particle RT (proton beam therapy and C-ion RT)Median OS: 24.6 monthsPresent study11C-ion RTMedian OS: 36.4 months, 3y-OS: 64%^a^Review article^†^*Abbreviations: C-ion RT* carbon ion radiotherapy, *HAIC* hepatic arterial infusion chemotherapy, *OS* overall survival, *RT* radiotherapy, *TACE* transarterial chemoembolization, *3y-OS* 3-year overall survival

The results of our study showed that patients with higher D~98~ for CTV tended to have locally controlled tumors, including local recurrence of more than 5 years after C-ion RT (Fig. [3](#Fig3){ref-type="fig"}). Indeed, two patients with locally controlled tumors and low CTV D~98~ who were prescribed a dose of 52.8 Gy (RBE), and all patients with CTV D~98~ who received more than 53 Gy (RBE), had no local recurrence with long-term local control after C-ion RT. This result suggested that high-dose C-ion beam administration can achieve local control, which may result in long-term local recurrence-free survival. Previous studies compared DVH for tumorous and normal liver between C-ion RT and X-ray RT (SBRT and IMRT) \[[@CR10], [@CR11]\]. Particularly for LAHCC, which is a large tumor or/and a tumor with irregular shapes, the dose required for the normal liver may be higher than that used for HCC, which has no macroscopic vascular invasion. Higher doses delivered to the normal liver resulted in a higher risk of radiation-induced liver disease \[[@CR30]\]; the prescribed dose must therefore be decreased to avoid development of radiation-induced liver disease. It is therefore difficult to administer sufficient tumor control doses for LAHCC with X-ray RT. In contrast, C-ion RT can decrease the dose delivered to the healthy liver while administering a sufficient dose to the tumor, due to its higher achievable dose concentration owing to the sharp lateral penumbra and distal tail-off.

Yoon et al. showed that TACE combined with X-ray RT resulted in improved prognosis compared with molecular targeted therapy alone \[[@CR5]\]. In terms of dose distribution, C-ion RT showed higher dose concentrations than X-ray RT \[[@CR10], [@CR11]\]; therefore, C-ion RT can result in reduced dose distribution to the healthy liver region without reducing the dose delivered to the tumor, thereby preserving liver function. If liver function can be preserved, the number of treatment options for preventing HCC recurrence may be increased. Liver function preservation is crucial for HCC patients who may need repeat treatment because of frequent recurrences, such as in cases of LAHCC. In our study, nine patients needed multiple treatments for recurrent tumors (Table [2](#Tab2){ref-type="table"}), and it may be possible that liver function preservation after C-ion RT enabled multiple treatment rounds after recurrence. Therefore, C-ion RT offers the advantage of liver function preservation during HCC treatment compared with X-ray RT, and TACE combined with C-ion RT may confer better prognosis than TACE combined with X-ray RT.

Proton beam therapy may be one of the treatment options for LAHCC in multidisciplinary treatment because of its higher dose concentration compared to X-ray RT \[[@CR29], [@CR31]\]. In terms of the dose fractionation schedule, proton beam therapy needs 8--38 fractions depending on the tumor location. In contrast, C-ion RT needs only 4 or 12 fractions. When combined with other anti-cancer therapies in multidisciplinary treatment, a shorter dose fractionation schedule offers an advantage in terms of the overall treatment time for planned sequential treatment. and may therefore improve the prognosis.

Our study had several limitations. First, this study was a single-institution retrospective analysis with a small number of patients. Second, there were a small number of patients with the most advanced stage of HCC involving a major branch of the portal or hepatic vein, such as the Vp4 and Vv3. Therefore, clinical outcomes observed here may have appeared favorable. Third, only the patients who were likely to benefit from local treatment were analyzed in the current study. The other reports of anti-cancer treatment for LAHCC included patients in whom systemic therapy was indicated, with little scope for local treatment; this patient bias may have affected survival rates.

Conclusions {#Sec12}
===========

Although LAHCC remains difficult to cure, C-ion RT-based multidisciplinary treatment showed favorable clinical outcomes with a high rate of local control and minimal toxicity. This finding suggests that C-ion RT may be a useful treatment option in the multidisciplinary therapy of LAHCC in patients who are likely to benefit from local treatment.
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